Archive
See details of previously published customer updates from our Health products team.
Showing 1 - 20 of 96 results
See details of previously published customer updates from our Health products team.
The final report on the safety of Building 23 by the independent expert review team has been completed.
Planning is now underway for a second repatriation project which is scheduled to take place in 2022. Find out more information.
ANSTO has released the Independent Safety Review of Building 23 - Nuclear medicine production facility.
Principal Technical Consultant Michael Druce shares some personal insights on the design and construction of ANSTO's nuclear medicine facility.
The new facility will be built around a product line of ANSTO’s design – a new Technetium-99m generator – that will enable greater process automation than is possible with existing technology, leading to improvements in efficiency, quality and importantly the highest levels of production safety.
The nuclear medicine community has welcomed the Australian Government’s decision to provide $30 million in funding to ANSTO for the design of a new nuclear medicine manufacturing facility.
Latest information on the scheduled supply of our nuclear medicine production.
ANSTO manufacture and supply a range of radiopharmaceuticals, radiochemicals, kits and accessories for use in research, industry and the health sector.
In May 2023, The Honourable Dr Annabelle Bennett, ANSTO Board Chair, shared ANSTO's Statement of Intent with the Minister for Industry, Science and Technology.
ANSTO is taking its innovative ANSTO Synroc® and CORIS360® technologies to the world stage at the Waste Management Symposia 2024 in Phoenix, Arizona USA this week (10 – 14 March 2024). Joining over 45 other countries and around 3,000 attendees, an Australian Government contingent comprising of ANSTO and the Australian Radioactive Waste Agency is in attendance to showcase Australia’s extensive radioactive waste management capabilities.
Be the first to find out the latest news regarding nuclear science and technology products, services, and innovation.
Australia’s nuclear agency ANSTO is continuing to lead planning efforts to repatriate what is called a TN-81 cask of intermediate-level radioactive from the United Kingdom in 2022.
Radioisotopes are widely used in medicine, industry, and scientific research. New applications for radioisotopes are constantly being developed.
(ANSTO) has welcomed the launch of the new National Science Statement and revitalised National Science and Research Priorities by Minister for Industry and Science, The Hon Ed Husic MP and Australia’s Chief Scientist, Dr Cathy Foley AO PSM.